Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: European Infant Neuroblastoma Study Group - 1999

Registration Number: NCT00025597

Locations: 🇦🇹
St. Anna Children's Hospital, Vienna, Austria
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇬🇧
Bristol Royal Hospital for Children, Bristol, England, United Kingdom

and more 8 locations

Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-26

Lead Sponsor: Societe Internationale d'Oncologie Pediatrique

Target Recruit Count: 65

Registration Number: NCT00004224

Locations: 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇸🇪
Ostra Sjukhuset, Gothenburg, Sweden
🇪🇸
Hospital Des Cruces, Vizcaya, Spain

and more 4 locations

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-12

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 340

Registration Number: NCT00012051

Locations: 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱
HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, Netherlands

and more 14 locations

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

Phase 3

Completed

Conditions: Untreated Childhood Medulloblastoma
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

Interventions: Drug: cisplatin
Drug: cyclophosphamide
Drug: vincristine sulfate
Drug: etoposide
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 82

Registration Number: NCT00006461

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Phase 3

Conditions: Carcinoma of Unknown Primary

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Academisch Ziekenhuis Maastricht

Target Recruit Count: 140

Registration Number: NCT00003558

Locations: 🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma

Phase 2

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 260

Registration Number: NCT00025064

Locations: 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧
Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧
Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom

and more 17 locations

Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma

Phase 2

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-07

Lead Sponsor: Children's Cancer and Leukaemia Group

Registration Number: NCT00024193

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Registration Number: NCT00017225

Locations: 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪
Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪
Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany

and more 85 locations

Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-02

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 75

Registration Number: NCT00025103

Locations: 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom

and more 17 locations

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: carmustine
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Drug: etoposide
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-02

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 397

Registration Number: NCT00004031

Locations: 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy